[Skip to Content]
[Skip to Content Landing]
From The JAMA Network
June 2016

Tumor-Treating Fields—A Fundamental Change in Locoregional Management for Glioblastoma

Author Affiliations
  • 1Department of Radiation Medicine, Northwell Health System, Lake Success, New York
  • 2Hofstra Northwell School of Medicine, Lake Success, New York
JAMA Oncol. 2016;2(6):813-814. doi:10.1001/jamaoncol.2016.0081

Few advances have been made in the treatment of glioblastoma multiforme since 2005 when Stupp et al1 demonstrated a 2-month improvement in median survival with the addition of temozolomide to standard radiation treatment and established the current standard of care. Glioblastoma remains a nearly always fatal diagnosis with a median survival of 14 to 16 months and progression of disease frequently seen within the first 6 months after treatment completion. Multifarious approaches to overcome the innate therapeutic resistance of glioblastoma have been exercises in futility, including radiation dose escalation, attempts to overcome or exploit hypoxia within tumors, interference with tumor-driven angiogenesis, targeting EGFR overexpression, and all manners of cytotoxic chemotherapies.

First Page Preview View Large
First page PDF preview
First page PDF preview